<i>Lycium barbaru</i>m glycopeptide ameliorates aberrant neuronal activity via ER stress modulation in ventral forebrain organoids derived from depressive patients.

ABSTRACT: Major depressive disorder (MDD) is a debilitating psychiatric condition associated with substantial personal, societal, and economic costs. Despite considerable advances in research, most conventional antidepressant therapies fail to achieve adequate response in a significant proportion of patients, underscoring the need for novel, mechanism-based interventions. Lycium barbarum glycopeptide (LbGp), a bioactive compound with emerging neuroprotective properties, has been proposed as a candidate for antidepressant development; however, its therapeutic efficacy and underlying mechanisms remain largely uncharacterized. In this study, ventral forebrain organoids were generated from patients with MDD to investigate disease-related neurophysiological abnormalities. These organoids exhibited

SUBMITTER: Tao MD 

PROVIDER: S-EPMC12464367 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature